21st Jun 2016 11:09
LONDON (Alliance News) - GW Pharmaceuticals PLC said Tuesday it has been granted an orphan drug designation for its key treatment epidiolex for the treatment of infantile spasms, which will be its fourth target indication for its epidiolex programme.
The company expects to begin a two-part phase III study in this indication in the fourth quarter of 2016, it said.
Infantile spasms are a specific type of seizure seen in an childhood epilepsy known as West Syndrome.
Epidiolex is already in development for three other indications in the field of pediatric epilepsy - Dravet syndrome, Lennox-Gastaut syndrome, and Tuberous Sclerosis complex.
"We are pleased to add infantile spasms as a fourth target indication for Epidiolex, demonstrating GW's ongoing commitment to addressing the significant unmet medical need within the field of pediatric epilepsy," said Chief Executive Officer Justin Gover in a statement.
Shares in GW Pharmaceuticals were down 1.2% at 521.00 pence Tuesday.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
GWP.L